These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacovigilance in India: how safe are the new drugs? How sure are we? Joshi SR; Sapatnekar SM J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970 [No Abstract] [Full Text] [Related]
5. Advantages of adverse-effect reporting by patients. Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228 [No Abstract] [Full Text] [Related]
6. A model for the future conduct of pharmacovigilance. Waller PC; Evans SJ Pharmacoepidemiol Drug Saf; 2003; 12(1):17-29. PubMed ID: 12616844 [TBL] [Abstract][Full Text] [Related]
7. An underrecognized challenge in evaluating postmarketing drug safety. Roden DM Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350 [No Abstract] [Full Text] [Related]
8. [Organization and results of drug vigilance in France]. Bégaud B; Chaslerie A; Haramburu F Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001 [TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance in clinical dentistry: overlooked or axiomatic? Carnelio S; Khan SA; Rodrigues G Gen Dent; 2011; 59(1):24-8; quiz 29-30, 80. PubMed ID: 21613036 [TBL] [Abstract][Full Text] [Related]
10. Decision support methods for the detection of adverse events in post-marketing data. Hauben M; Bate A Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799 [TBL] [Abstract][Full Text] [Related]
11. European commission consultation on pharmacovigilance. Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839 [No Abstract] [Full Text] [Related]
12. Safety in numbers--monitoring risk in approved drugs. Okie S N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493 [No Abstract] [Full Text] [Related]
13. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
14. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587 [No Abstract] [Full Text] [Related]
15. Methods for improving the reporting of adverse effects. Prescrire Int; 2011 Mar; 20(114):71. PubMed ID: 21648229 [No Abstract] [Full Text] [Related]
16. Detection of adverse drug reaction signals using an electronic health records database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) algorithm. Yoon D; Park MY; Choi NK; Park BJ; Kim JH; Park RW Clin Pharmacol Ther; 2012 Mar; 91(3):467-74. PubMed ID: 22237257 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacovigilance: a case of phantom ships and Russian roulette]. Stricker BH Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668 [TBL] [Abstract][Full Text] [Related]